Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
NeoTX Therapeutics Ltd.
NeoTX Therapeutics Ltd.
Incyte Corporation
Sotio Biotech Inc.
Molecular Templates, Inc.
Xencor, Inc.
AbbVie
AbbVie
Incyte Corporation
Incyte Corporation
Abramson Cancer Center at Penn Medicine
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)